Recent corporate developments include announcements of new board and shareholder votes and a clinical trial related to Isomyosamine, reflecting ongoing activity in legacy pharmaceutical assets amid the company’s strategic transition.

• TNF Pharmaceuticals announced new board and shareholder votes in April 2026, indicating governance changes during the strategic transition [N1].
• TNF Pharmaceuticals and Renova Health announced a clinical trial to explore Isomyosamine in December 2024, reflecting continued activity in pharmaceutical programs [N2].

The company’s exclusive license with LightSolver and its development of the qc-LPU100 position it to address significant market needs in energy-efficient blockchain infrastructure, decentralized physical infrastructure networks, and AI high-performance computing. The potential performance and energy efficiency advantages of LPUs over traditional GPUs and QPUs could create economic incentives for adoption. The company’s patent portfolio and strategic initiatives to expand intellectual property and engage early adopters support its technology leadership. The divestiture or licensing of legacy pharmaceutical assets could provide capital to accelerate laser-based computing commercialization.

The company’s laser-based computing technology remains in early prototype stages with no significant revenue, creating uncertainty about successful development, validation, and market acceptance. The transition from pharmaceuticals to laser computing involves execution risks, including technology integration, manufacturing scalability, and customer adoption. The company faces intense competition from well-established semiconductor and biotech firms with greater resources. Regulatory complexities, capital requirements, and potential dilution from preferred stock obligations pose financial risks. Intellectual property protection may be challenged, and cybersecurity incidents have occurred. The legacy pharmaceutical business faces clinical and regulatory risks and may require divestiture or restructuring.

Q/C Technologies' moat is primarily based on its exclusive global licensing agreement with LightSolver Ltd. for laser processing unit technology, which is a specialized photonic computing approach targeting energy-efficient blockchain and AI applications. The company's patent portfolio, including numerous issued U.S. and foreign patents, provides intellectual property protection for both its laser-based computing and pharmaceutical assets. However, the moat is challenged by competition from established semiconductor companies, emerging photonic and quantum computing firms, and the rapidly evolving nature of blockchain infrastructure. The company's limited operating history in laser-based computing and reliance on successful technology development and commercialization also constrain its competitive advantage.

• Execution Risk in New Technology Development: The qc-LPU100 and laser-based computing business are in early development stages with prototype validation and commercialization uncertain. Failure to achieve performance, scalability, or customer adoption targets could materially impact the business.
• Capital Requirements and Financing Constraints: Significant additional capital is required to develop, certify, manufacture, and commercialize the qc-LPU100. Financing may be dilutive or unavailable, potentially forcing delays or reductions in operations.
• Intellectual Property Protection: The company’s competitive position depends on maintaining and enforcing patents and licenses. Patent challenges, design-arounds, or loss of licensing rights could impair operations.
• Regulatory and Compliance Risks: The company operates in heavily regulated industries including pharmaceuticals, export controls, and blockchain infrastructure. Changes or failures in compliance could delay commercialization or limit market access.
• Competition: The company faces competition from established semiconductor, photonic, quantum computing firms, and biotech companies with greater resources and market presence.
• Limited Operating History and Staffing: The company has a limited operating history in laser-based computing and minimal staffing, which may constrain its ability to execute strategy and scale operations.
• Financial Obligations to Preferred Stockholders: Dividend and redemption obligations to Series H Preferred Stockholders may require substantial cash outflows, affecting liquidity and operational flexibility.
• Cybersecurity Risks: Past cybersecurity incidents, including wire fraud, highlight ongoing risks that could result in financial loss or operational disruption.

• Q/C Technologies, Inc. historically developed therapeutic platforms including Isomyosamine and Supera-CBD but has shifted focus to laser-based computing for blockchain and cryptocurrency infrastructure using quantum-class laser-based computing technology (S1).
• The company holds an exclusive global licensing agreement with LightSolver Ltd. to deploy laser processing units (LPUs), including the qc-LPU100, designed to perform complex computations with improved speed and energy efficiency compared to traditional computing architectures (S1).
• The qc-LPU100 targets complex combinatorial and physical problems, including partial differential equations, with applications in cryptocurrency infrastructure, decentralized physical infrastructure networks (DePin Tokens), and AI-driven high-performance computing (S1).
• The company is currently in prototype development, internal validation, and early-stage benchmarking of the qc-LPU100, focusing on performance testing, integration, and scalability (S1).
• No significant revenue has been generated from the laser-based computing business; commercialization depends on prototype validation, customer adoption, and securing additional capital (S1).
• The company is evaluating divestiture of its legacy pharmaceutical assets to fund the new strategic focus (S1).
• The legacy pharmaceutical business includes clinical-stage programs for Isomyosamine (targeting autoimmune diseases and age-related frailty) and Supera-CBD (targeting epilepsy, pain, anxiety/depression) (S1).
• The company’s intellectual property portfolio includes 19 issued U.S. patents, 70 foreign patents, and 4 pending foreign patent applications related to both laser-based computing and pharmaceutical programs, with patents expiring between 2036 and 2041 (S1, S2).
• As of December 31, 2025, the company had two full-time employees and no part-time employees (S1).
• Financial snapshot as of December 31, 2025: cash and equivalents of $986,996; short-term investments of $14,801,267; current assets of $16,580,558; current liabilities of $5,532,042; current ratio of 3.0; cash ratio of 2.85 (S1).
• The company incurred a net loss of $11,627,122 for the year ended December 31, 2025, with basic and diluted EPS of -$8.66 (S1).
• The company faces significant competition in laser-based computing from semiconductor companies producing CPUs, GPUs, AI hardware, and emerging photonic, optical, and quantum computing firms, as well as blockchain infrastructure providers (S1).
• The company faces competition in pharmaceuticals from biotech and pharmaceutical companies developing therapies targeting inflammatory pathways and cannabinoid-based therapeutics (S1).
• The company’s business is subject to extensive regulation including FDA requirements for pharmaceuticals and export controls, FCC and UL certifications for hardware, and evolving regulations on cryptocurrency and blockchain infrastructure (S1).
• The company’s financial condition is affected by obligations to holders of Series H Preferred Stock, including dividend payments and restrictive covenants that may limit financing flexibility (S2, S3).
• Recent corporate developments include new board and shareholder votes announced in April 2026 and a clinical trial announcement in December 2024 related to Isomyosamine (N1, N2).
• The company has limited operating history in laser-based computing, increasing uncertainty about its ability to execute the new strategy and commercialize products (S1, S2).
• The company’s ability to protect and enforce intellectual property rights is critical but uncertain, with risks of patent challenges and design-arounds by competitors (S2).
• The company requires significant additional capital to develop and commercialize the qc-LPU100 and may face challenges raising capital on acceptable terms (S1, S2).
• Cybersecurity incidents have occurred, including a wire fraud event in July 2023 with identified losses, leading to enhanced security measures (S1).